A Randomized, Open-label Trial Comparing Telbivudine vs, Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2012-2014

ABSTRACT

The goal of chronic hepatitis B (CHB) treatment is complete and permanent eradication of hepatitis B virus (HBV) from patient's body, which is best represented by serum HBsAg loss accompanied by undetectable serum HBV DNA level. While the most recently approved nucleos(t)ide analogues (NA) have marked antiviral potency and can induce HBV DNA undetectability in the majority of patients through prolonged treatment, NA need to be given long term, almost indefinitely, in most cases because they suppress HBV DNA only during therapy. For example, even after HBeAg-loss by a potent NA, suppression of serum HBV DNA to undetectable level is sustained only in about 23%-37% at 24 weeks off treatment. Thus, continuous therapy with NA until HBsAg clearance remains necessary in a majority of cases. The recent availability of commercial quantitative assays of serum hepatitis B surface antigen (HBsAg) has enabled quantitative HBsAg to be used as a biomarker for prognosis and treatment response in CHB. It has been suggested that HBsAg decline during lamivudine or entecavir therapy is slower and less pronounced compared to interferon treatment, despite a higher effect on HBV DNA suppression. Based on HBsAg kinetics, it has been estimated that the predicted median time to HBsAg loss in patients treated with lamivudine or entecavir is more than 30 years. Thus, treatment that can induce rapid decline of HBsAg would have clear advantage in reducing the treatment duration required to achieve HBsAg-loss. Interestingly, in a recent preliminary study, 24-weeks of treatment with telbivudine has induced HBsAg decline as comparable to pegylated interferon treatment. Although there has been no head-to-head trial comparing NAs in inducing HBsAg decline, previous studies consistently suggested that the decline of HBsAg is greater during telbivudine treatment compared with lamivudine or entecavir. Thus, in this clinical trial, the investigators will investigate whether telbivudine is more effective in inducing HBsAg decline compared with entecavir in HBeAg-positive CHB patients who have achieved undetectable serum HBV DNA by preceding entecavir treatment. Detailed Description A single-center randomized active-controlled open-label superiority trial - Patients will be randomly assigned 1:1 to receive telbivudine (600 mg/day) or ongoing entecavir (0.5 mg/day) for 48 weeks. - Eligible patients will be randomized using blocks of permuted treatment assignments after stratification by HBsAg level (1,000 IU/mL-5,000 IU/mL and ≥5,000 IU/mL IU/mL) and by entecavir treatment duration (1 year-2 year, ≥2 year). - Because over 98% of Korean patients with CHB have HBV genotype C,9 HBV genotype will not determined or be regarded as a stratification factor. - There will be no interruption in entecavir therapy before randomization. - Patients' treatment information will be retrospectively collected during entecavir treatment phase as well (DNA change, HBeAg status, HBsAg titre, ALT, and treatment duration. etc) - Patients will be screened within 4 weeks before randomization to determine study eligibility. More... »

URL

https://clinicaltrials.gov/show/NCT01595685

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The goal of chronic hepatitis B (CHB) treatment is complete and permanent eradication of hepatitis B virus (HBV) from patient's body, which is best represented by serum HBsAg loss accompanied by undetectable serum HBV DNA level. While the most recently approved nucleos(t)ide analogues (NA) have marked antiviral potency and can induce HBV DNA undetectability in the majority of patients through prolonged treatment, NA need to be given long term, almost indefinitely, in most cases because they suppress HBV DNA only during therapy. For example, even after HBeAg-loss by a potent NA, suppression of serum HBV DNA to undetectable level is sustained only in about 23%-37% at 24 weeks off treatment. Thus, continuous therapy with NA until HBsAg clearance remains necessary in a majority of cases. The recent availability of commercial quantitative assays of serum hepatitis B surface antigen (HBsAg) has enabled quantitative HBsAg to be used as a biomarker for prognosis and treatment response in CHB. It has been suggested that HBsAg decline during lamivudine or entecavir therapy is slower and less pronounced compared to interferon treatment, despite a higher effect on HBV DNA suppression. Based on HBsAg kinetics, it has been estimated that the predicted median time to HBsAg loss in patients treated with lamivudine or entecavir is more than 30 years. Thus, treatment that can induce rapid decline of HBsAg would have clear advantage in reducing the treatment duration required to achieve HBsAg-loss. Interestingly, in a recent preliminary study, 24-weeks of treatment with telbivudine has induced HBsAg decline as comparable to pegylated interferon treatment. Although there has been no head-to-head trial comparing NAs in inducing HBsAg decline, previous studies consistently suggested that the decline of HBsAg is greater during telbivudine treatment compared with lamivudine or entecavir. Thus, in this clinical trial, the investigators will investigate whether telbivudine is more effective in inducing HBsAg decline compared with entecavir in HBeAg-positive CHB patients who have achieved undetectable serum HBV DNA by preceding entecavir treatment.\n\nDetailed Description\nA single-center randomized active-controlled open-label superiority trial - Patients will be randomly assigned 1:1 to receive telbivudine (600 mg/day) or ongoing entecavir (0.5 mg/day) for 48 weeks. - Eligible patients will be randomized using blocks of permuted treatment assignments after stratification by HBsAg level (1,000 IU/mL-5,000 IU/mL and \u22655,000 IU/mL IU/mL) and by entecavir treatment duration (1 year-2 year, \u22652 year). - Because over 98% of Korean patients with CHB have HBV genotype C,9 HBV genotype will not determined or be regarded as a stratification factor. - There will be no interruption in entecavir therapy before randomization. - Patients' treatment information will be retrospectively collected during entecavir treatment phase as well (DNA change, HBeAg status, HBsAg titre, ALT, and treatment duration. etc) - Patients will be screened within 4 weeks before randomization to determine study eligibility.", 
    "endDate": "2014-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01595685", 
    "keywords": [
      "open-label trial", 
      "serum", 
      "patient", 
      "chronic hepatitis", 
      "HBV DNA", 
      "CHB", 
      "eradication", 
      "hepatitis B virus", 
      "body", 
      "hepatitis B virus DNA", 
      "nucleos", 
      "Na", 
      "antiviral potency", 
      "majority", 
      "prolonged treatment", 
      "long term", 
      "therapy", 
      "suppression", 
      "undetectable level", 
      "continuous therapy", 
      "clearance", 
      "recent availability", 
      "quantitative assay", 
      "Hepatitis B Surface Antigen", 
      "biomarker", 
      "prognosis", 
      "treatment response", 
      "decline", 
      "lamivudine", 
      "interferon treatment", 
      "kinetics", 
      "median time", 
      "rapid decline", 
      "clear advantage", 
      "treatment duration", 
      "recent preliminary study", 
      "pegylated interferon", 
      "head-to-head", 
      "previous study", 
      "clinical trial", 
      "single center", 
      "eligible patient", 
      "treatment assignment", 
      "stratification", 
      "IU/mL", 
      "genotype", 
      "interruption", 
      "Random Allocation", 
      "treatment information", 
      "treatment phase", 
      "DNA change", 
      "status", 
      "titre", 
      "ALT", 
      "eligibility"
    ], 
    "name": "A Randomized, Open-label Trial Comparing Telbivudine vs, Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B Who Have Achieved Serum HBV DNA Undetectability by Preceding Entecavir Treatment", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01595685"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00012.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.413967.e", 
        "type": "Organization"
      }
    ], 
    "startDate": "2012-05-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/s12876-017-0572-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053954450", 
          "https://doi.org/10.1186/s12876-017-0572-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12876-017-0572-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053954450", 
          "https://doi.org/10.1186/s12876-017-0572-2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01595685"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01595685'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01595685'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01595685'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01595685'


 

This table displays all metadata directly associated to this object as RDF triples.

78 TRIPLES      16 PREDICATES      71 URIs      64 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01595685 schema:about anzsrc-for:3053
2 schema:description The goal of chronic hepatitis B (CHB) treatment is complete and permanent eradication of hepatitis B virus (HBV) from patient's body, which is best represented by serum HBsAg loss accompanied by undetectable serum HBV DNA level. While the most recently approved nucleos(t)ide analogues (NA) have marked antiviral potency and can induce HBV DNA undetectability in the majority of patients through prolonged treatment, NA need to be given long term, almost indefinitely, in most cases because they suppress HBV DNA only during therapy. For example, even after HBeAg-loss by a potent NA, suppression of serum HBV DNA to undetectable level is sustained only in about 23%-37% at 24 weeks off treatment. Thus, continuous therapy with NA until HBsAg clearance remains necessary in a majority of cases. The recent availability of commercial quantitative assays of serum hepatitis B surface antigen (HBsAg) has enabled quantitative HBsAg to be used as a biomarker for prognosis and treatment response in CHB. It has been suggested that HBsAg decline during lamivudine or entecavir therapy is slower and less pronounced compared to interferon treatment, despite a higher effect on HBV DNA suppression. Based on HBsAg kinetics, it has been estimated that the predicted median time to HBsAg loss in patients treated with lamivudine or entecavir is more than 30 years. Thus, treatment that can induce rapid decline of HBsAg would have clear advantage in reducing the treatment duration required to achieve HBsAg-loss. Interestingly, in a recent preliminary study, 24-weeks of treatment with telbivudine has induced HBsAg decline as comparable to pegylated interferon treatment. Although there has been no head-to-head trial comparing NAs in inducing HBsAg decline, previous studies consistently suggested that the decline of HBsAg is greater during telbivudine treatment compared with lamivudine or entecavir. Thus, in this clinical trial, the investigators will investigate whether telbivudine is more effective in inducing HBsAg decline compared with entecavir in HBeAg-positive CHB patients who have achieved undetectable serum HBV DNA by preceding entecavir treatment. Detailed Description A single-center randomized active-controlled open-label superiority trial - Patients will be randomly assigned 1:1 to receive telbivudine (600 mg/day) or ongoing entecavir (0.5 mg/day) for 48 weeks. - Eligible patients will be randomized using blocks of permuted treatment assignments after stratification by HBsAg level (1,000 IU/mL-5,000 IU/mL and ≥5,000 IU/mL IU/mL) and by entecavir treatment duration (1 year-2 year, ≥2 year). - Because over 98% of Korean patients with CHB have HBV genotype C,9 HBV genotype will not determined or be regarded as a stratification factor. - There will be no interruption in entecavir therapy before randomization. - Patients' treatment information will be retrospectively collected during entecavir treatment phase as well (DNA change, HBeAg status, HBsAg titre, ALT, and treatment duration. etc) - Patients will be screened within 4 weeks before randomization to determine study eligibility.
3 schema:endDate 2014-12-01T00:00:00Z
4 schema:keywords ALT
5 CHB
6 DNA change
7 HBV DNA
8 Hepatitis B Surface Antigen
9 IU/mL
10 Na
11 Random Allocation
12 antiviral potency
13 biomarker
14 body
15 chronic hepatitis
16 clear advantage
17 clearance
18 clinical trial
19 continuous therapy
20 decline
21 eligibility
22 eligible patient
23 eradication
24 genotype
25 head-to-head
26 hepatitis B virus
27 hepatitis B virus DNA
28 interferon treatment
29 interruption
30 kinetics
31 lamivudine
32 long term
33 majority
34 median time
35 nucleos
36 open-label trial
37 patient
38 pegylated interferon
39 previous study
40 prognosis
41 prolonged treatment
42 quantitative assay
43 rapid decline
44 recent availability
45 recent preliminary study
46 serum
47 single center
48 status
49 stratification
50 suppression
51 therapy
52 titre
53 treatment assignment
54 treatment duration
55 treatment information
56 treatment phase
57 treatment response
58 undetectable level
59 schema:name A Randomized, Open-label Trial Comparing Telbivudine vs, Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B Who Have Achieved Serum HBV DNA Undetectability by Preceding Entecavir Treatment
60 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01595685
61 schema:sdDatePublished 2019-03-07T15:24
62 schema:sdLicense https://scigraph.springernature.com/explorer/license/
63 schema:sdPublisher Nb2f09c2cf74a44018517ab9d18ef2bd3
64 schema:sponsor https://www.grid.ac/institutes/grid.413967.e
65 schema:startDate 2012-05-01T00:00:00Z
66 schema:subjectOf sg:pub.10.1186/s12876-017-0572-2
67 schema:url https://clinicaltrials.gov/show/NCT01595685
68 sgo:license sg:explorer/license/
69 sgo:sdDataset clinical_trials
70 rdf:type schema:MedicalStudy
71 Nb2f09c2cf74a44018517ab9d18ef2bd3 schema:name Springer Nature - SN SciGraph project
72 rdf:type schema:Organization
73 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
74 rdf:type schema:DefinedTerm
75 sg:pub.10.1186/s12876-017-0572-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053954450
76 https://doi.org/10.1186/s12876-017-0572-2
77 rdf:type schema:CreativeWork
78 https://www.grid.ac/institutes/grid.413967.e schema:Organization
 




Preview window. Press ESC to close (or click here)


...